Beaupre Darrin 4

What Happened
Darrin Beaupre, Chief Medical Officer of IDEAYA Biosciences (IDYA), was granted a derivative award for 175,000 shares on January 30, 2026. The Form 4 reports the acquisition as an award/derivative (code A) with a reported price of $0.00 in the filing; this reflects the grant reporting format and does not by itself describe any exercise price or immediate cash value. This was an award (not a sale), typically part of executive compensation rather than an open-market purchase.

Key Details

• Transaction date: 2026-01-30; Form 4 filed: 2026-02-02 (filed within the normal Form 4 reporting window).
• Reported amount: 175,000 shares (derivative securities — option/award). Reported price: $0.00 in the filing.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnote (vesting): 25% vests on the first anniversary measured from Jan 1, 2026 (the Vesting Commencement Date), then 1/48th of total shares vest each month thereafter; 100% vests on the fourth anniversary.
• No indication in the filing that shares were sold or exercised immediately; this is a time-vesting award.

Context
This appears to be a standard equity award to an executive that vests over four years — such grants are common for aligning executive incentives with company performance and retention. Because it's a derivative award with a vesting schedule, it does not represent immediately tradable shares and should not be interpreted as an immediate buy/sell signal. The filing does not state exercise/strike price or whether other compensation terms apply; those details may appear in the company’s proxy or other SEC filings.